REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could fewer zaps of radiation work just as well for lymphoma?
Disease control Recruiting nowThis study compares a reduced dose of radiation (3 treatments) against the standard 12 treatments for people with indolent non-Hodgkin lymphoma, a slow-growing blood cancer. The goal is to see if the shorter course is safer and still controls the disease. About 112 adults with ce…
Matched conditions: REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-phase trial tests a new type of CAR T-cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target three cancer marker…
Matched conditions: REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC